Reading Time: 4 minutesThe harsh reality of drug and device development is that the majority of new therapies never make it to market. Less than one in ten investigational products in non-oncology successfully navigate Phase I through regulatory approval, and this figure drops to nearly one in twenty in oncology. Operational hurdles add more difficulty, as more than […]
Article




